• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23290 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2014     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Development of composite indicators to measure the quality of prevention and chronic management activities for gynecological cancer screening in primary care]
2014     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Development of appropriateness criteria for transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Development of a shared knowledge system for network assessment of technological innovation in medicine]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Development of a scientific concept for the generation of routine practice data and their analysis for benefit assessments according to §35a Social Code Book (SGB) V in the event of market access for several drugs of one drug class]
2006     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Development of a prognosis model to identify effects of threshold values on health care]
2015     National Evidence-based Healthcare Collaborating Agency (NECA) [Development of a preference-based instrument: Asian Comparative Study]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Development of a model for predicting emergency hospital admission and readmission in Catalonia]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Development of a decision aid for aortic aneurysm interventions]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Development of a basic set of expert consensus-based quality indicators for the care delivered to stroke patients]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Development framework for social services practice guidelines]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Development and validation of methods for quality assessment of health technologies assessments reports : assessment of ethical issues in health technologies assessment]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Development and validation of methods for quality assessment of health technologies assessment reports]
2012     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Development and validation of methods for quality assessment of health technologies assessment reports. Evaluation of the quality of qualitative studies]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Development and evaluation of tools designed in order to ensure patient safety for possible incorporation into the management of healthcare processes]
2010     Canary Health Service [Development and evaluation of a decision support tool for benign prostatic hyperplasia patients]
2012     The Netherlands Organisation for Health Research and Development (ZonMw) [Development and application of clinical prediction models in the presence of multilevel data]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Deucravacitinib (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Determining optimal intervals for screening and surveillance: using individualized risk estimates to increase cost-effectiveness]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Determination of the SHI target population for the therapeutic indication type 2 diabetes mellitus using SHI routine data]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Determination of antigen expression levels of uPA and PAI-1 in primary breast cancer with intermediate recurrence risk after R0 primary surgery]
2023     Canary Health Service [Determination by chemiluminescence of autoantibodies to domain 1 of beta 2 glycoprotein I in patients with antiphospholipid syndrome]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Detection of sperm DNA fragmentation (TUNEL, SCSA, SCD, COMET) and use of annexin columns (MACS) in assisted reproduction treatments]
2024     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Detection of IDH1 mutations in cholangiocarcinoma patients]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Detection of high risk human papillomavirus E6 and E7 oncogenes for cervical cancer screening]
2014     Haute Autorite de sante (HAS) [Detection of enterovirus genome in cerebrospinal fluid by gene amplification in meningitis patients]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Detection and diagnosis of Alzheimer's disease and other neurocognitive disorders]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Detecting COPD in persons over 50 years with persistent cough in general practice: comparison of cost-effectiveness of diagnostic strategies]
2012     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [DETECTA-T]
2011     Health Intervention and Technology Assessment Program (HITAP) [Designing a decision frame for making health resource allocation decisions: a case study in Thailand]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Design of an interaction protocol between Primary Care and Hospitals to improve early detection and monitoring of patients with multiple sclerosis]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Design and validation of a screening tool for evaluating the health impact of regional policies]
2010     Basque Office for Health Technology Assessment (OSTEBA) [Design and implementation plan of telemedicine in specific clinical areas: telemonitoring and teledermatology. Assessment of initial results and costs]
2021     Center for Drug Evaluation (CDE) [Descriptive study and comparative effectiveness of listed medications for osteoporosis on new osteoporotic fracture event in osteoporosis patients by using National Health Insurance claim database]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan]
2005     Basque Office for Health Technology Assessment (OSTEBA) [Description of the elaboration of a clinical practice guidelines for asthma in the autonomous community of the Basque country by means of a mixed method of adaptation-development-actualization]
2021     Norwegian Institute of Public Health (NIPH) [Description and quality assessment of guidelines for tonsillectomy in patients with recurrent tonsillitis: mapping review]
2013     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) for corneal endothelial dysfunction]
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [Depression in chronically ill elderly]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Depression in children and adolescents: does psychotherapy lead to better results compared to other therapies?]
2009     Haute Autorite de sante (HAS) [Dental prostheses with ceramic and/or milled cores (full assessment)]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Dental indications for standardised procedures of instrumental functional analysis under consideration of health economic aspects]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Dental indications for standardised procedures of instrumental functional analysis under consideration of health economic aspects]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Denosumab for the treatment of solid tumor bone metástasis]
2008     Andalusian Health Technology Assessment Area (AETSA) [Denaturing high performance liquid chromatography (DHPLC). Use and utility in massive genotyping]
2011     Committee for New Health Technology Assessment (CNHTA) [Deletion of 18q choromosome in colorectal cancer (LOH, loss of heterozygosity)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Delamanid (pulmonary multi-drug resistant tuberculosis, body weight >= 10 kg) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Defibrillators in public places]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Deferred parathyroid autograft with cryopreserved tissue for the surgical management of hyperparathyroidism]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Deep brain stimulation using electrodes in the treatment of Parkinson's Disease]
2010     Andalusian Health Technology Assessment Area (AETSA) [Deep brain stimulation in the treatment of depressive and obsessive-complusive disorders]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Deep brain stimulation in patients with treatment-resistant depressive disorder, obsessive compulsive disorder and Tourette syndrome]
2013     Canary Health Service [Deep brain stimulation in neurological and psychiatric disorders]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Deep brain stimulation for Parkinson's disease]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Deep brain stimulation for dystonia refractory to medical treatment]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Deep anterior lamellar keratoplasty in keratoconus]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decitabine/cedazuridine (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decitabine - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2021     Canary Health Service [Decisional flowchart for patient involvement in health technology assessments]
2010     Canary Health Service [Decision-making aid tools for patients with depression]
2007     Canary Health Service [Decision-making aid tools for patients with benign prostatic hyperplasia]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany]
2024     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Decision support software in ultrasound diagnosis for the classification of breast nodules]
2008     Andalusian Health Technology Assessment Area (AETSA) [Decision making tool for patients with non valvular atrial fibrillation]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Decision Making Process for Safety Issues in Health Services and Technologies]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid knee endoprosthesis]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for hip joint replacement]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for gallbladder removal]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for defibrillators and pacemakers]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for biomarker tests in breast cancer - Addendum to Commission D14-01]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for back surgery]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for amputations in diabetic foot syndrome - Rapid Report]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for ablation in cardiac arrhythmia]
2010     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Decentralized cooperation for development in health and environment: Assessment of barriers and opportunities]
2011     Committee for New Health Technology Assessment (CNHTA) [Debridement using hydrosurgery system]
2012     Haute Autorite de sante (HAS) [Day surgery: an overview]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Day surgery: a systematic overview]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Data-supported timely management in cooperation with a centre for telemedicine for patients with advanced cardiac failure - rapid report]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dasabuvir/ombitasvir/paritaprevir/ritonavir (Addendum to Commissions A15-03 and A15-04)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dasabuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darvadstrocel (perianal fistulas in Crohn disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darunavir-cobicistat-emtricitabine-tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darolutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darolutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darolutamide (prostate cancer) - Addendum to Commission A23-21]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darolutamide (prostate cancer) - Addendum to Commission A20-43]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daridorexant (insomnia) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daridorexant (insomnia) - Addendum to Commission A22-123]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daridorexant (chronic insomnia) - Benefit assessment according to § 35a SGB V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Daratumumab for relapsed or refractory multiple myeloma]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (systemic light chain amyloidosis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, stem cell transplant unsuitable) - Addendum to Commission A20-14]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, stem cell transplant suitable) - Addendum to Commission A20-15]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]